Publications by authors named "M Bukhtiyarova"

Flow hydrogenation performed over heterogeneous catalysts makes organic synthesis more economical, safe and environmentally friendly. Over the past two decades, a significant amount of research with a major focus on noble metal catalysts has been carried out in this area. However, catalysts based on non-noble metals (Ni, Cu, Co, .

View Article and Find Full Text PDF
Article Synopsis
  • A multidrug-resistant Gram-negative bacterium is causing serious infections and poses a growing health threat, making new treatment options essential.
  • Researchers are focusing on inhibiting the MsbA transporter, which is crucial for the bacterium's survival.
  • They optimized a compound known as cerastecin D, which showed promising antibacterial activity and effectiveness in mouse models for treating infections.
View Article and Find Full Text PDF

Carbapenem-resistant Acinetobacter baumannii infections have limited treatment options. Synthesis, transport and placement of lipopolysaccharide or lipooligosaccharide (LOS) in the outer membrane of Gram-negative bacteria are important for bacterial virulence and survival. Here we describe the cerastecins, inhibitors of the A.

View Article and Find Full Text PDF

Many research papers describe selective hydrogenation of functional groups, such as nitro groups, carbonyl groups, or unsaturated carbon bonds to obtain fine chemicals or precursors of pharmaceuticals. Quite often, the catalyst performance is investigated in batch or continuous flow reactors without finding advantages and disadvantages of this or that regime. At the same time, the transition from batch processes to continuous flow occurs on the industrial scale.

View Article and Find Full Text PDF

Antiretroviral therapy inhibits HIV-1 replication but is not curative due to establishment of a persistent reservoir after virus integration into the host genome. Reservoir reduction is therefore an important HIV-1 cure strategy. Some HIV-1 nonnucleoside reverse transcriptase inhibitors induce HIV-1 selective cytotoxicity in vitro but require concentrations far exceeding approved dosages.

View Article and Find Full Text PDF